Background: As AIDS patients live longer, the management of co-morbidities becomes increasingly important. Previous studies from developed countries give conflicting results as to whether co-infection with hepatitis C virus (HCV) lowers the life expectancy of individuals with AIDS.
Methods: This retrospective cohort study was based on a medical record review of a nationally representative sample of 2821 adult AIDS cases diagnosed in 1995 and 1996 in Brazil. We compared the characteristics and survival of patients known to be positive and negative for HCV.
Results: A total of 833 patients received HCV testing, and the prevalence was 33%. HCV-positive patients received less intensive antiretroviral treatment. The crude mortality was greater for HCV-positive patients (hazard ratio 1.26; P = 0.04), but HCV status was not a significant predictor in a multivariate analysis that included other predictors of survival.
Conclusion: Brazilian AIDS patients with hepatitis C have a shorter survival than those without, but this seems to be mainly as a result of their receiving less antiretroviral treatment. We cannot say whether this is because of the fear of hepatotoxicity, an inability to tolerate treatment, or for other reasons. To improve survival, these patients need optimal treatment of their HIV disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.aids.0000191487.69414.88 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New recommendations of Spanish Society of Emergency Medicine (SEMES) for emergency department diagnosis of HIV infection based on results from Spain's "Leave Your Mark" program.
Emergencias
December 2024
Servicio de Urgencias, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, España.
Hidden infections and late diagnoses are currently the main challenges of the HIV pandemic. Emergency departments (EDs) are one of the health care system's key resources addressing these challenges. In 2020, the Spanish Society of Emergency Medicine (SEMES) published recommendations for ordering HIV serology testing for patients with certain health conditions, and in 2021 SEMES launched the "Leave Your Mark" (Deja tu Huella - DTH) program to facilitate implementing the recommendations during emergency care.
View Article and Find Full Text PDFPembrolizumab Leads to Complete Response in an HIV Patient With a Solid Tumor and a Cluster of Differentiation 4 (CD4) Count Less Than 100.
Cureus
December 2024
Hematology/Oncology, University of Kansas Medical Center, Kansas City, USA.
A 58-year-old male, with a history of human immunodeficiency virus (HIV) and stage 4 left frontotemporal squamous cell carcinoma (SCC), presented with new-onset neck pain. He was diagnosed with HIV five years prior. The patient had a cluster of differentiation 4 (CD4) count of 53 cells/mm³ and a high viral load, later suppressed with bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).
View Article and Find Full Text PDFRevisiting Age-Related Normative Hearing Levels in Korea.
J Korean Med Sci
January 2025
Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Hanyang University, Seoul, Korea.
Background: Hearing level reference values based on the results of recent audiometry have not been established for the general population of South Korea. This study aimed to evaluate the mean hearing levels of each age group and to measure the annual progression of hearing loss.
Methods: We used the database of the eighth and ninth Korea National Health and Nutrition Examination Survey from 2020 to 2022, and included participants with normal tympanic membranes and without occupational noise exposure.
Background: Accurate estimates of incremental cost (IC) attributable to antimicrobial resistance (AMR) provide information of immense public health importance to the policy makers. Here, we present the IC from patient perspective for treating antimicrobial-resistant pathogens in India.
Methods: This cohort study was conducted in eight hospitals including government (GH), private (PH) and trust hospitals (TH), considering their ownership, geographical location and categories of cities.
Cohort profile: the potentially preventable burden of community-acquired pneumonia in South African adults in the era of widespread PCV13 immunisation and antiretroviral therapy roll-out, before and during the COVID-19 pandemic - the multicentre, multimethod PotPrev Study.
BMJ Open
December 2024
Perinatal HIV Research Unit (PHRU), University of the Witwatersrand Johannesburg, Johannesburg, Gauteng, South Africa.
Purpose: In the setting of an established childhood pneumococcal vaccination programme with immediate initiation and treatment of antiretroviral therapy (ART) for people living with HIV (PLWH), the risk of adult pneumococcal community-acquired pneumonia (CAP) is not recently described. We aimed to investigate CAP incidence, recurrence, mortality, risk factors and microbiology before and during the COVID-19 pandemic.
Participants: Adults aged ≥18 years were enrolled in three South African provinces from March 2019 to October 2021, with a brief halt during the initial COVID-19 lockdown.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!